1
Return

Hepatitis B Virus Reactivation Risk With IL-17, IL-23/IL-12, or JAK Inhibitors: A Systematic Review and Meta-Analysis

delete2026-06-13
delete0
PRE
AI
M
Marouf Alhalabi *
H
Hussam Aldeen Alshiekh
DOI：10.1111/liv.70708delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
This study aimed to determine the incidence of hepatitis B virus reactivation (HBVr) in patients with chronic or occult HBV infection who were treated with IL-12/23, IL-23 (together referred to as anti-IL-23/12), IL-17, or JAK inhibitors without antiviral prophylaxis. In addition, we sought to assess whether the risk of HBVr varies according to anti-HBs status among individuals who are anti-HBc positive.
Keywords:
cytokine inhibitors
hepatitis B virus
IL-12/23 inhibitors
IL-17 inhibitors
IL-23 inhibitors
JAK inhibitors

Journal

Liver International cover
Liver International
IF:
5.2
Papers:
6.6K
Citations:
1.5W

Organization

M
Ministry of Health
Scholars:
1.0K
Papers: 475
Citations: 43
D
Damascus Hospital
Scholars:
3
Papers: 2
Citations: 20
Cited Papers

Cited Papers

Citing Papers

Citing Papers